Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Medicine That'll Make You Sick


What will Big Pharma come up with next?

The global pharmaceuticals market is expected to reach $967 billion by 2011, which is why companies are always looking for that next must-have drug. But bringing new drugs to market is a timely and costly process. That's why Big Pharma's latest innovations aren't new drugs, they're new syndromes and disorders. Like Restless Leg Syndrome. Or Excessive Sleepiness. Companies can use preexisting drugs to treat these new disorders, saving time and money.

What often goes unreported, however, are the sometimes strange side effects these drugs have. GlaxoSmithKline's (GSK) Requip, for example, helps to relax restless legs. But it also causes excessive sexual urges, hallucinations and compulsive gambling. Cephalon's (CEPH) Provigil, which treats Excessive Sleepiness, causes depression, anxiety, psychosis, mania and thoughts of suicide. But, hey, at least you'll feel alive as you contemplate your nervous suicidal breakdown.

This week, Hoofy and Boo take a look at this new phenomenon, and experience a few side effects of their own.
< Previous
  • 1
Next >
No positions in stocks mentioned.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

Featured Videos